Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | PTGFR | P43088 | 1/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535995 | 0.94 | KMT2A (0.38) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL3213624 | 0.91 | BTK (0.37) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL19747528 | 0.88 | KMT2A (0.38) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL16244146 | 0.87 | MEN1 (0.34) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL1536186 | 0.84 | MEN1 (0.40) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL22237434 | 0.83 | GAA (0.32) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL18038894 | 0.82 | KMT2A (0.41) | BTKKMT2AMEN1MAPK1DPP8 | |
| SCHEMBL28961660 | 0.81 | KMT2A (0.38) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL3210704 | 0.81 | MEN1 (0.35) | BTKKMT2AMEN1MAPK1CTSL | |
| SCHEMBL20940177 | 0.81 | MEN1 (0.35) | BTKKMT2AMEN1MAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326154-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326154-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | CBR1, CYCS, CYP3A43 | BTK 1870/4885KMT2A 3162/4885MEN1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.